Compare ATMU & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | XENE |
|---|---|---|
| Founded | 1958 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 2023 | 2014 |
| Metric | ATMU | XENE |
|---|---|---|
| Price | $52.39 | $44.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $49.00 | ★ $53.55 |
| AVG Volume (30 Days) | ★ 845.4K | 757.2K |
| Earning Date | 11-07-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | ★ 11.13 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $1,724,400,000.00 | $7,500,000.00 |
| Revenue This Year | $6.37 | N/A |
| Revenue Next Year | $4.11 | N/A |
| P/E Ratio | $21.87 | ★ N/A |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $30.94 | $26.74 |
| 52 Week High | $53.56 | $45.32 |
| Indicator | ATMU | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 65.85 |
| Support Level | $50.30 | $42.36 |
| Resistance Level | $53.56 | $45.01 |
| Average True Range (ATR) | 1.61 | 1.45 |
| MACD | 0.39 | 0.31 |
| Stochastic Oscillator | 84.58 | 92.62 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. The company designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.